## Randolph J Noelle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3459436/publications.pdf

Version: 2024-02-01

64 papers 7,010 citations

36 h-index 59 g-index

83 all docs 83 docs citations

83 times ranked 6584 citing authors

#	Article	lF	CITATIONS
1	Retinoic acid signaling acts as a rheostat to balance Treg function. , 2022, 19, 820-833.		8
2	Rethinking peripheral T cell tolerance: checkpoints across a T cell's journey. Nature Reviews Immunology, 2021, 21, 257-267.	22.7	122
3	Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. Blood, 2021, 137, 1090-1103.	1.4	8
4	VISTA regulates microglia homeostasis and myelin phagocytosis, and is associated with MS lesion pathology. Acta Neuropathologica Communications, 2021, 9, 91.	5 <b>.</b> 2	5
5	Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, $2021,8,.$	6.0	19
6	VISTA Re-programs Macrophage Biology Through the Combined Regulation of Tolerance and Anti-inflammatory Pathways. Frontiers in Immunology, 2020, 11, 580187.	4.8	24
7	Exploring the VISTA of microglia: immune checkpoints in CNS inflammation. Journal of Molecular Medicine, 2020, 98, 1415-1430.	3.9	17
8	VISTA: Coming of age as a multi-lineage immune checkpoint. Clinical and Experimental Immunology, 2020, 200, 120-130.	2.6	66
9	VISTA is a checkpoint regulator for na $\tilde{A}$ ve T cell quiescence and peripheral tolerance. Science, 2020, 367, .	12.6	156
10	VISTA: A Target to Manage the Innate Cytokine Storm. Frontiers in Immunology, 2020, 11, 595950.	4.8	24
11	VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity. Seminars in Immunology, 2019, 42, 101308.	5.6	92
12	Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Cancer Immunology Research, 2019, 7, 1079-1090.	3.4	129
13	Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality. Journal of Immunology, 2019, 202, 2795-2805.	0.8	10
14	Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness. Frontiers in Immunology, 2019, 10, 2641.	4.8	39
15	VISTA Is a Novel Regulator of Macrophage Biology. Blood, 2019, 134, 2320-2320.	1.4	3
16	Blocking the VISTA pathway enhances disease progression in (NZB × NZW) F1 female mice. Lupus, 202 210-216.	18, 27, 1.6	27
17	VISTA expression by microglia decreases during inflammation and is differentially regulated in CNS diseases. Glia, 2018, 66, 2645-2658.	4.9	57
18	VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival. Cancer Immunology, Immunotherapy, 2018, 67, 1113-1121.	4.2	79

#	Article	lF	Citations
19	Immunoregulatory functions of <scp>VISTA</scp> . Immunological Reviews, 2017, 276, 66-79.	6.0	154
20	VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis. Arthritis and Rheumatology, 2017, 69, 814-825.	5.6	56
21	Functions of CD40 and Its Ligand, gp39 (CD40L). Critical Reviews in Immunology, 2017, 37, 371-420.	0.5	106
22	VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes. Arthritis Research and Therapy, 2017, 19, 270.	3.5	44
23	Retinoic Acid Signaling in B Cells Is Required for the Generation of an Effective T-Independent Immune Response. Frontiers in Immunology, 2016, 7, 643.	4.8	14
24	A New VISTA on combination therapy for negative checkpoint regulator blockade. , 2016, 4, 86.		36
25	IL-33 enhances retinoic acid signaling on CD4+ T cells. Cytokine, 2016, 85, 120-122.	3.2	6
26	Seeing through the dark: New insights into the immune regulatory functions of vitamin A. European Journal of Immunology, 2015, 45, 1287-1295.	2.9	100
27	Diversity of gut microflora is required for the generation of B cell with regulatory properties in a skin graft model. Scientific Reports, 2015, 5, 11554.	3.3	29
28	Allospecific CD4 <sup>+</sup> T cells retain effector function and are actively regulated by Treg cells in the context of transplantation tolerance. European Journal of Immunology, 2015, 45, 2017-2027.	2.9	17
29	CCR6-Dependent Positioning of Memory B Cells Is Essential for Their Ability To Mount a Recall Response to Antigen. Journal of Immunology, 2015, 194, 505-513.	0.8	76
30	Leukocyte Homing, Fate, and Function Are Controlled by Retinoic Acid. Physiological Reviews, 2015, 95, 125-148.	28.8	32
31	Selective Involvement of the Checkpoint Regulator VISTA in Suppression of B-Cell, but Not T-Cell, Responsiveness by Monocytic Myeloid-Derived Suppressor Cells from Mice Infected with an Immunodeficiency-Causing Retrovirus. Journal of Virology, 2015, 89, 9693-9698.	3.4	44
32	Retinoic Acid Is Essential for Th1 Cell Lineage Stability and Prevents Transition to a Th17 Cell Program. Immunity, 2015, 42, 499-511.	14.3	130
33	Role of retinoic acid in the stability of the T-helper-type 1 lineage and implications for autoimmunity. Lancet, The, 2015, 385, S25.	13.7	0
34	Cutting Edge: Retinoic Acid Signaling in B Cells Is Essential for Oral Immunization and Microflora Composition. Journal of Immunology, 2015, 195, 1368-1371.	0.8	49
35	Disruption of the immune-checkpoint <i>VISTA</i> gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14846-14851.	7.1	156
36	VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy. Cancer Immunology Research, 2014, 2, 510-517.	3.4	187

#	Article	IF	Citations
37	VISTA Is an Immune Checkpoint Molecule for Human T Cells. Cancer Research, 2014, 74, 1924-1932.	0.9	378
38	VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Research, 2014, 74, 1933-1944.	0.9	377
39	Retinoic acid on stage in antitumor immunity. Oncolmmunology, 2013, 2, e22985.	4.6	1
40	VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. Journal of Experimental Medicine, 2011, 208, 577-592.	8.5	539
41	Cellular sources and immune functions of interleukin-9. Nature Reviews Immunology, 2010, 10, 683-687.	22.7	256
42	Determinations of B Cell Fate in Immunity and Autoimmunity. , 2004, 8, 1-24.		27
43	The Balance Between Donor T Cell Anergy and Suppression Versus Lethal Graft-Versus-Host Disease Is Determined by Host Conditioning. Journal of Immunology, 2002, 169, 5581-5589.	0.8	41
44	Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood, 2001, 98, 467-474.	1.4	93
45	Cd4+Cd25+ Immune Regulatory Cells Are Required for Induction of Tolerance to Alloantigen via Costimulatory Blockade. Journal of Experimental Medicine, 2001, 193, 1311-1318.	8.5	536
46	IMMUNOLOGY: Long Live the Mature B Cell–a BAFFling Mystery Resolved. Science, 2001, 293, 2012-2013.	12.6	28
47	Lineage-Restricted Function of Nuclear Factor κB–Inducing Kinase (Nik) in Transducing Signals via Cd40. Journal of Experimental Medicine, 2000, 191, 381-386.	8.5	67
48	A RANDOMIZED PHASE II TRIAL COMPARING TWO DIFFERENT SEQUENCE COMBINATIONS OF AUTOLOGOUS VACCINE AND HUMAN RECOMBINANT INTERFERON Î <sup>3</sup> AND HUMAN RECOMBINANT INTERFERON α2B THERAPY II PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: CLINICAL OUTCOME AND ANALYSIS OF IMMUNOLOGICAL PARAMETERS. Journal of Urology, 2000, 163, 1322-1327.	N <sub>0.4</sub>	52
49	Activation and regulation of the $\hat{\mathbb{I}}^{\circ}B$ kinase in human B cells by CD40 signaling. European Journal of Immunology, 1999, 29, 1353-1362.	2.9	34
50	CD40 and its ligand in cell-mediated immunity. , 1998, 49, 17-22.		10
51	IMMUNE REGULATION BY CD40 AND ITS LIGAND GP39. Annual Review of Immunology, 1996, 14, 591-617.	21.8	634
52	Induction of Immunological Tolerance to Islet Allografts. Cell Transplantation, 1996, 5, 49-52.	2.5	48
53	Therapeutic potential for blockade of the CD40 ligand, gp39. Journal of Clinical Immunology, 1996, 16, 83-89.	3.8	30
54	Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. European Journal of Immunology, 1995, 25, 596-603.	2.9	208

#	Article	lF	CITATIONS
55	Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. European Journal of Immunology, 1995, 25, 3053-3059.	2.9	415
56	The Role of CD40 and its Ligand in the Regulation of the Immune Response. Immunological Reviews, 1994, 138, 23-37.	6.0	80
57	A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 6550-6554.	7.1	758
58	Cognate interaction between T helper cells and B cells. VII. Role of contact and lymphokines in the expression of germ-line and mature gamma 1 transcripts. Journal of Immunology, 1992, 149, 1164-9.	0.8	17
59	T helper cellâ€dependent B cell activation. FASEB Journal, 1991, 5, 2770-2776.	0.5	80
60	Cognate interactions between helper T cells and B cells. V. Reconstitution of T helper cell function using purified plasma membranes from activated Th1 and Th2 T helper cells and lymphokines. Journal of Immunology, 1991, 146, 1118-24.	0.8	61
61	Patch-clamp profile of ion channels in resting murine B lymphocytes. Journal of Membrane Biology, 1990, 114, 175-188.	2.1	19
62	Cognate interactions between helper T cells and B cells. III. Contact-dependent, lymphokine-independent induction of B cell cycle entry by activated helper T cells. Journal of Immunology, 1989, 143, 1807-14.	0.8	67
63	Cognate interactions between helper T cells and B cells. I. Cloning and helper activity of a lymphokine-dependent helper T cell clone (Th-3). The Journal of Molecular and Cellular Immunology: JMCI, 1989, 4, 161-73; discussion 173-5.	0.5	0
64	Thymus-Dependent Antigenic Stimulation of Hapten-Specific B Lymphocytes. Immunological Reviews, 1987, 99, 173-192.	6.0	20